Added 1 month ago Drug news
Amgen has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
Added 2 months ago Drug news
Rolontis is non inferior to pegfilgrastim for mamagement of severe chemotherapy- induced neutropenia.- Spectrum Pharma
Spectrum Pharmaceuticals, Inc. announced that the first Phase III study of Rolontis (eflapegrastim), ADVANCE, has met its primary endpoint of...
Added 3 months ago Drug news
Generon Corporation announced that the first pivotal phase III study in the U.S. for F 627 to treat chemotherapy-induced neutropenia...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.
What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.
Febrile neutropaenia is the development of fever, often with other signs of infection, in a patient with neutropaenia, an abnormally low number of neutrophil granulocytes in the blood.
Added 8 years ago
Neutropenic sepsis is a potentially fatal complication of anticancer treatment (particularly chemotherapy). Mortality rates ranging between 2% and 21% have...
Added 5 years ago
Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network.
Ascertainment of cases and disease classification is an acknowledged problem for epidemiological research into haematological malignancies.
Added 7 months ago
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
Background: Hypomethylating drugs are the standard treatment for patients with high-risk myelodysplastic syndromes. Survival is poor after failure of these...
Added 2 years ago